Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma

Urology

Volumn 53, Issue 1, 1999, Pages 44-49

  Carducci, Michael A ^a,b   Piantadosi, Steven ^a   Pound, Charles R ^b   Epstein, Jonathan I ^a,b   Simons, Jonathan W ^a,b   Marshall, Fray F ^a,b   Partin, Alan W ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL MODEL;

CARCINOMA, RENAL CELL; CELL NUCLEUS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 0032904029     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00440-3     Document Type: Article

References (26)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
2. Thrasher J.B., Paulson D.F. Prognostic factors in renal cancer. Urol Clin North Am. 20:1993;247-262.
3. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med. 335:1996;865-875.
4. Elson P.J., Witte R.S., Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48:1988;7310-7313.
5. Simons J.W., Jaffee E.M., Weber C., et al. Bioactivity of human GM-CSF gene transfer in autologous irradiated renal cell carcinoma vaccines. Cancer Res. 57:1997;1537-1546.
6. Motzer R.J., Schwartz L., Law T.M., et al. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma antitumor activity in a Phase II trial and interactions in vitro . J Clin Oncol. 13:1995;1950-1957.
7. Rabinovitch R.A., Zelefsky M.J., Gaynor J.J., et al. Patterns of failure following surgical resection of renal cell carcinoma implications for adjuvant local and systemic therapy . J Clin Oncol. 12:1994;206-212.
8. Virchow RLK: Die Krankhaften Geschwulste: Dressig Volesungen Gehalted Wahrend des Wintersemesters 1862-1863 an der Universtat zu Berlin. A Hirschwarl, 1863, p 1.
9. Diamond D.A., Berry S.J., Umbricht C., et al. Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate. 3:1982;321-327.
10. Gilchrist K.W., Hogan T.F., Harberg J., et al. Prognostic significance of nuclear sizing in renal cell carcinoma. Urology. 24:1984;122-124.
11. Furhman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:1982;655-663.
12. Tosi P., Luzi P., Baak J.P.A., et al. Nuclear morphometry as an important prognostic factor in stage 1 renal cell carcinoma. Cancer. 58:1986;2512-2518.
13. Murphy G.F., Partin A.W., Maygarden S.J., et al. Nuclear shape analysis for assessment of prognosis in renal cell carcinoma. J Urol. 143:1990;1103-1107.
14. Donhuijsen K., Schulz S., Ledder L.D. Nuclear grading of renal cell carcinomas - is morphometry necessary? J Cancer Res Clin Oncol. 117:1991;73-78.
15. Gutierrez J.L., Buelta L., Val-Bernal J.F., et al. Nuclear morphometry in prognosis of renal adenocarcinoma. Urology. 39:1992;130-134.
16. Pound C.R., Partin A.W., Epstein J.I., et al. Nuclear morphometry accurately predicts recurrence in clinically localized renal cell carcinoma. Urology. 42:1993;243-248.
17. Delahunt B., Becker R.L., Bethwaite P.B., et al. Computerized nuclear morphometry and survival in renal cell carcinoma comparison with other prognostic indicators . Pathology. 26:1994;353-358.
18. Ruiz J.L., Hernandez M., Martinez J., et al. Value of morphometry as an independent prognostic factor in renal cell carcinoma. Eur Urol. 27:1995;54-57.
19. Nativ O., Sabo E., Raviv G., et al. The role of nuclear morphometry for predicting disease outcome in patients with localized renal cell carcinoma. Cancer. 76:1995;1440-1444.
20. Mohler J.L., Partin A.W., Lohr W.D., et al. Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of digitization system. J Urol. 139:1988;1080-1084.
21. Mohler J.L., Partin A.W., Epstein J.I., et al. Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. J Urol. 139:1988;1085-1089.
22. Mohler J.L., Figlesthaler W.M., Zhang X.Z., et al. Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. Cancer. 74:1994;2996-3001.
23. Borland R.N., Partin A.W., Epstein J.I., et al. The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J Urol. 149:1993;272-275.
24. Piantadosi S. Clinical Trials A Methodologic Perspective . 1997;1-590 John Wiley, New York.
25. Kaplan E.M., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
26. Partin A.W., Yoo J.K., Crooks D., et al. Prediction of disease-free survival after therapy in Wilms' tumor using nuclear morphometric techniques. J Pediatr Surg. 29:1994;456-460.